News Release Archive

This section features CSL Behring news releases that are more than 18 months old. Click the tabs to select releases in your area of interest. Click Resources to find additional background material on CSL Behring.

All Releases
Bleeding Disorders
Hereditary Angioedema (HAE)
Fluid Management


21 September 2016 CSL Behring Reinforces Global Leadership at the 17th Biennial Meeting of the European Society for Immunodeficiencies (ESID)

CSL Behring is proud to be a platinum sponsor of the 17th Biennial Meeting of the European Society for Immunodeficiencies (ESID) this week in Barcelona.

> Read More
23 June 2016 CSL Behring Announces Immunoglobulin Research Grant Winners

CSL Behring announced today at the Peripheral Nerve Society’s Inflammatory Neuropathy Consortium (INC) meeting at the University of Glasgow, Scotland, the winners of its annual Interlaken Leadership Awards.

> Read More
24 February 2016 CSL Behring Adds Isoagglutinin Reduction Step to Privigen® Manufacturing Process

Global biotherapeutics leader CSL Behring today announced an enhancement to its manufacturing process for Privigen® with the addition of the Ig IsoLo® step.

> Read More
23 February 2016 First Export of Privigen® From New Manufacturing Facility in Broadmeadows, Melbourne, Australia

Global biotherapeutics leader CSL Behring today announced an increase in the global supply of Privigen® as the first export has been shipped from a new state-of-the-art manufacturing facility in Broadmeadows, Melbourne, Australia.

> Read More
29 June 2015 CSL Behring Announces the 2015 Interlaken Leadership Awards Recipient

CSL Behring announced today that Mohammad Alsharabati, MD, University of Alabama at Birmingham, United States, is the recipient of the 2015 Interlaken Leadership Award for original research in the field of neuroimmunology. This annual global awards program provides monetary grants and/or product supply for investigational use to support research focusing on the potential role of immunoglobulin (Ig) therapy in the treatment of neurological disorders. The global review committee seeks proposals likely to advance innovative medical research and knowledge about the potential role of Ig therapy to improve the lives of patients who have disabling neurological conditions.

> Read More
Page 1 of 10 Next | Last

LinkedIn Twitter Facebook Google+